BEIJING (Xinhua): China's drug authority has approved clinical tests for an inhaled Covid-19 vaccine co-developed by domestic company CanSino Biologics, the Agence France-Presse (AFP) reported on Tuesday (March 23).
The clinical trial application of the vaccine, jointly developed by CanSino and the Beijing Institute of Biotechnology, was approved by the National Medical Products Administration (NMPA) on Monday, the pharmaceutical firm said in a filing on the Hong Kong stock exchange on Tuesday.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
